PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.29
D/E ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.12. Howard Marks would check for debt covenant compliance and refinancing risks.
49.85
Dangerously high net debt exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.26. Michael Burry would check for debt covenant compliance and refinancing risks.
-6.67
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
2.36
Current ratio 75-90% of Drug Manufacturers - Specialty & Generic median of 2.75. John Neff would demand higher margins to compensate for tighter liquidity.
51.19%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 8.59%. Michael Burry would check for aggressive accounting and hidden risks.